RAR and RXR modulation in cancer and metabolic disease

Autor: Hinrich Gronemeyer, Lucia Altucci, Kathleen M. Ogilvie, Angel R. de Lera, Mark D. Leibowitz
Přispěvatelé: Institut de génétique et biologie moléculaire et cellulaire (IGBMC), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Louis Pasteur - Strasbourg I, Université Louis Pasteur - Strasbourg I-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Rok vydání: 2007
Předmět:
MESH: Diabetes Mellitus
Receptors
Retinoic Acid
medicine.drug_class
Retinoic acid
Retinoid X receptor
Biology
Ligands
Retinoids
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Neoplasms
Drug Discovery
Diabetes Mellitus
MESH: Ligands
medicine
Humans
MESH: Obesity
MESH: Neoplasms
MESH: Retinoids
Obesity
Retinoid
Receptor
neoplasms
Transcription factor
030304 developmental biology
MESH: Receptors
Retinoic Acid
Pharmacology
Clinical Trials as Topic
0303 health sciences
MESH: Humans
Retinoid X receptor alpha
Cell growth
MESH: Clinical Trials
organic chemicals
Cancer
[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry
Molecular Biology/Molecular biology
General Medicine
medicine.disease
biological factors
3. Good health
body regions
Retinoid X Receptors
chemistry
030220 oncology & carcinogenesis
embryonic structures
Cancer research
MESH: Retinoid X Receptors
Zdroj: dressNature Reviews Drug Discovery
dressNature Reviews Drug Discovery, 2007, 6 (10), pp.793-810. ⟨10.1038/nrd2397⟩
ISSN: 1474-1784
1474-1776
Popis: Retinoic acid receptors (RARs) are ligand-controlled transcription factors that function as heterodimers with retinoid X receptors (RXRs) to regulate cell growth and survival. The success of RAR modulation in the treatment of acute promyelocytic leukaemia (APL) has stimulated considerable interest in the development of RAR and RXR modulators. This has been aided by recent advances in the understanding of the biological role of RARs and RXRs and in the design of selective receptor modulators that might overcome the limitations of current drugs. Here, we discuss the challenges and opportunities for therapeutic strategies based on RXR and RAR modulators, with a focus on cancer and metabolic diseases such as diabetes and obesity.
Databáze: OpenAIRE
Externí odkaz: